Evaxion (EVAX) Q3 2026 earnings review
Evaxion cuts its costs, but it still sells new shares
Evaxion, a Danish company that designs cancer vaccines with artificial intelligence, spent less while it kept selling new shares. Research spending fell 25% from a year ago, so by our math cash burn matched the pace its yearly plan required. Chief executive Helen Tayton-Martin reported three-year results showing lasting responses to EVX-01, its melanoma vaccine. Evaxion sold $2.2 million of new shares, and it says cash now lasts towards the end of next year.
| Revenue | $0 $7.5M a year ago, a one-time licence fee |
|---|---|
| Operating costs | $3.7M โ18% from a year ago |
| Cash | $13.3M $14.0M at the end of June |
| How long cash lasts | Extended towards the end of 2027, from the second half of 2027 |
โ๏ธ Verdict: ๐ข Bullish
The story got better because spending slowed as the cash plan needed, and the vaccine data held up. The bad news: no partner has signed a new deal in four quarters, so share sales still pay for each extra month of cash.
The question now is whether a partner will pay for Evaxion's work before its cash runs out. Either a licence fee replaces share sales, or each owner's stake keeps shrinking. The EVX-04 filing due by year-end and the full-year results will tell.
๐ Bull Case
Vaccine Responses Lasted Three Years in Melanoma
EVX-01 is Evaxion's personalized cancer vaccine, which it designs for each patient's tumor with AI-Immunology, its software for picking vaccine targets. Chief executive Helen Tayton-Martin said the field around such vaccines has "changed more positively".
At the ESMO cancer congress in October, Evaxion presented three-year results from its trial in advanced melanoma, a skin cancer. It reported "89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up".
That matters because three years was the main test of whether responses fade, and Evaxion says they held. But the release gives no patient count, and the trial enrolled only 16 patients.
What to watch: the count of patients still responding at three years, which Evaxion has not published. A count near the two-year level would give partners a clear reason to license EVX-01.
Lower Research Spending Kept Cash Burn on Plan
Evaxion has no product sales, so spending decides how long its cash lasts. Its $14 million burn plan for 2026 needed, by our math, a much slower second half.
Evaxion cut research and development spending by 25% from a year ago and said the drop came "mainly due to reduced headcount". Overhead barely moved, so total operating costs shrank 18%.
By our math, the quarter burned about $2.9 million of cash, the pace the plan required. That matters because the plan rested on this slowdown, but one quarter does not settle it, since Evaxion's spending moves unevenly.
What to watch: full-year cash burn in the annual results. A figure at or below $14 million would show that cost cuts, not share sales, carry the plan.
Off-the-Shelf Leukemia Vaccine Nears First Human Trial
Evaxion also designs off-the-shelf vaccines, meaning one product can treat many patients instead of one. EVX-04, its vaccine for acute myeloid leukemia (AML), a blood cancer, targets tumor markers from endogenous retroviruses in what the release calls the "dark genome".
Tayton-Martin said Evaxion is "tracking towards" its last milestone of the year, the EVX-04 trial submission. The biotech will also show new target data at the ASH blood cancer meeting in December.
That matters because one vaccine for many patients is simpler to make and license than a custom one. But EVX-04 has not yet reached a patient, so its case still rests on lab work.
What to watch: whether Evaxion files the EVX-04 trial application by December 31. An on-time filing would keep its first off-the-shelf cancer vaccine on course for human testing.
๐ป Bear Case
Selling New Shares Made the Cash Last Longer
Evaxion said its cash now lasts "towards the end of 2027", later than the second half of 2027 it named before. The release credits sales of new shares for the change, not savings. An at-the-market programme lets Evaxion sell new stock directly on the exchange.
In the third quarter, those sales raised $2.2 million before fees. The weighted share count rose 3.6% from last quarter and 36% from a year ago. Each existing share therefore owns a smaller part of Evaxion.
Tayton-Martin pointed to "strong operational momentum", but by our math the extra months came from new money. Without the share sales, this quarter's burn would stretch cash only to about mid-2027, the date it gave before.
Evaxion also updated a filing so the European Investment Bank, a former lender, can resell shares from warrants it holds. The company wrote "We are not conducting a capital raise", but those warrants can still add shares.
What to watch: the share count in the full-year results, set against any partner payment. Share sales at this pace would keep each extra quarter of cash dependent on new investors.
No New Partner Deal for Four Quarters
Evaxion relies on partners that pay upfront fees and fund later trials. A year ago, the drugmaker MSD paid $7.5 million for EVX-B3, a bacterial vaccine, which made that quarter profitable.
This quarter Evaxion booked no revenue, and no new deal has arrived since Tayton-Martin took charge a year ago. The company said it remains in "multiple parallel partnership discussions", as it did last quarter.
That matters more after the refocus, because EVX-01's new uses, the infection vaccines and the autoimmune ideas all now need partner money. Evaxion will work on infection programs only "if funded by external partners".
What to watch: a signed licence or option with an upfront fee, which would appear as revenue. Such a deal would prove that partners will pay for the platform's data.
Risks This Quarter Didn't Answer
Four standing risks got no clear answer in this release. Each needs a specific disclosure, and most of them arrive with the full-year results or the EVX-04 trial filing.
- EVX-01 durability: the release reports lasting responses at three years but no patient count; the count would show any loss of responders.
- Rival vaccines: Moderna and Merck's personalized melanoma vaccine sits in a later-stage trial; an EVX-01 partner deal would show buyers still see room.
- EVX-04 timing: Evaxion says it remains on track to file by year-end; a slip into 2027 would test its planning.
- Funding climate: the release says nothing about partner or investor appetite; the pace of future share sales will reveal it.
What to watch: the EVX-01 patient count and the EVX-04 filing date, both due by the full-year results. Clear answers on both would retire two of these four risks.
๐ Other Themes
Evaxion Narrows Its Focus to Cancer Vaccines
Evaxion said it will put cancer vaccines first and "make some adjustments to its organization". Infection vaccines continue only with partner funding, and autoimmune work narrows to "concept validation for potential future partnerships". The company gave no job cuts, savings target or one-time charge, so nobody can yet measure the plan's effect on spending.
๐ฒ Other KPIs
Cash fell 5% from the end of June, a far smaller drop than in the two quarters before, because share sales covered part of the spending. Since December, cash has shrunk 43% from $23.2 million.
Equity, the value left for shareholders after all debts, dropped to less than half its December level because losses outran the money raised from share sales. It now equals 44% of total assets, against 60% at the end of last year.
Financial items turned into a small cost, against a $1.3 million gain a year ago. That gain came from the debt settlement with the European Investment Bank, partly offset by costs from revaluing warrants. The release calls this quarter's level normal for the business.
๐ฎ Guidance
Raised. Evaxion now says its cash lasts towards the end of 2027, a few months beyond its earlier date. The release credits share sales for the extra months. If the $14 million burn plan for this year still holds, by our math about $2.8 million remains for the fourth quarter.
Unchanged. Evaxion still plans to apply before year-end for the first human trial of EVX-04, its off-the-shelf vaccine for acute myeloid leukemia. Preclinical studies for the application continue. The other milestones for this year, including the October melanoma data, arrived on schedule.
New. Evaxion will present data on the targets EVX-04 aims at, at the American Society of Hematology meeting in New Orleans. The data come from lab work, not patients, so they test the choice of targets rather than the vaccine's effect in people.
โ Key Questions
How many EVX-01 patients still respond after three years?
The release reports lasting responses but gives no count. At the two-year mark, Evaxion counted 11 patients still responding. Partners will want the same measure now.
Does the $14 million cash-burn plan for 2026 still stand?
Evaxion repeated the plan in each earlier quarter but left it out of this release. The figure decides whether cash reaches the end of 2027 without more share sales.
How much can Evaxion still raise through share sales?
When last reported, the at-the-market programme let Evaxion sell up to $45.5 million of shares until March 2028. Investors need to know how much it has sold and what room remains.
Is the first EVX-04 trial paid for with current cash?
Evaxion plans to file the trial application by year-end, but it has not said whether the trial itself fits inside the cash it holds or needs a partner.
How many jobs does the reorganisation remove, and at what cost?
Evaxion said it will adjust its organization as it narrows its focus, but it gave no headcount, savings figure or one-time charge. Those numbers decide whether spending next year drops below this year's.
